- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07565246
A Study to Understand the Analgesic Properties of Topically Applied Menthol When Used in a Marathon.
A Real-world Evidence Study to Understand the Analgesic Properties of Topically Applied Menthol When Used in a Marathon.
The purpose of the research study is to gather the opinions and/or perceptions relating to the use of topically applied menthol and experience of pain during and after a marathon in adult runners (18+ years) participating in the 2025 Chicago Marathon. The main questions it aims to answer are:
- Does topically applied menthol reduce pain levels in marathon runners during recovery?
- How quickly does pain relief occur after topically applied menthol application?
- What are the sensory attributes (e.g., cooling sensation) associated with topically applied menthol use during and after the race?
- How do demographic factors (e.g., age, sex, menstrual cycle stage, sleep quality) influence pain experience and topically applied menthol effectiveness?
Researchers will compare pre- and post-application pain scores in the Recovery Application Zone to see if Biofreeze provides measurable pain relief and sensory benefits.
Participants will:
- Provide documented informed consent prior to participation.
- Self-select to use Biofreeze products during or after the race.
Complete one or both of the following:
- Recovery Application Zone Questionnaire (includes pain score before and after Biofreeze application, sensory assessments, demographics).
- End of Race Questionnaire (includes retrospective recall of pain relief, product use, sensory experience, and demographic data).
Przegląd badań
Szczegółowy opis
This is a real-world, observational study evaluating self-selected use of topically applied menthol among runners in the 2025 Chicago Marathon.
Participants independently choose whether to use topically applied menthol products, which products to use, and how frequently to apply them as part of their usual pain-management behaviour.
The study does not assign or administer any intervention. Data are collected from participants who voluntarily used topically applied menthol and chose to complete the questionnaires.
Participants may self-select to use topically applied menthol products during the race or recovery as they normally would. Researchers do not assign or direct product use. Product application occurs independently of study participation.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Illinois
-
Deerfield, Illinois, Stany Zjednoczone, 60015
- Curion Strategic Product Insights
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Participant has provided documented informed consent.
- Participant aged 18 years and above.
- Participant is entrant into the Chicago marathon 2025.
- Participant has self-selected to use topically applied menthol during the race or during immediate recovery.
- Comprehension of and able to read English.
Exclusion Criteria:
1. Employee of Sponsor or Agency/ vendor collecting the data
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
Chicago Marathon Runners who use topically applied menthol
|
Pain-experience observational study conducted during a marathon.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Mean Pain Score
Ramy czasowe: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
|
Pain relief was assessed by change in Numeric Rating Scale (NRS) 0-10 pre and post topical menthol application.
|
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Proportion of participants reporting pain relief within 10 seconds after completed application of topically applied menthol.
Ramy czasowe: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
|
Characterising the speed of analgesic effect from topically applied menthol in participants recovering from marathon. Number of subjects whose pain score based on 0-10 NRS rating reduced from pre-application to post-application, whose post-application score was within 10 seconds. |
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
|
|
Percentage of participants which report pain relief reduction of 2 points or greater on NRS within 10 seconds of topically applied menthol application.
Ramy czasowe: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
|
Characterising the speed of analgesic effect from topically applied menthol in participants recovering from marathon. Number of subjects whose pain score based on 0-10 Numerical Rating Scale rating reduced over 2 points from pre-application to post- application, whose post-application score was reported within 10 seconds. |
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
|
|
Percentage of participants reporting a cooling sensation within 10 seconds/ immediately after application.
Ramy czasowe: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
|
Percentage of participants reporting a cooling sensation within 10 seconds or immediately after application.
Participants reported if they experienced a cooling sensation (YES/ NO) and for the next question, reported if that occurred within 10 seconds / immediately after application or over 10 seconds.
|
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
|
|
Percentage of participants experiencing cooling sensation lasting 2 hours or more after topically applied menthol use
Ramy czasowe: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
Percentage of participants experiencing cooling sensation lasting 2 hours or more after topically applied menthol use, by product, participants who reported a cooling sensation (YES/ NO) and for the next question, participants reported duration of cooling assessed as follows: 1.Less than 10 minutes 2.10 minutes to less than 30 minutes 3.30 minutes to less than 60 minutes 4.60 minutes to less than 2 hours 5.2 hours to less than 3 hours 6.3 hours to less than 4 hours 7.4 hours or more |
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
|
Rating of Intensity from the use of topically applied menthol when used after the marathon
Ramy czasowe: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
|
Average rating for intensity from the use of topically applied menthol when used after the marathon. Intensity of cooling sensation is assessed post application of topically applied menthol, calculated using a 1-10 Rating Scale question to rate intensity of cooling sensation, where 1 is a mild cooling sensation, 10 is an extremely intense cooling sensation. |
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
|
|
Rating of Intensity from the use of topically applied menthol when used during the marathon
Ramy czasowe: Retrospective recall data from the end of race questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
Average rating for intensity from the use of topically applied menthol when used during the marathon. Intensity of cooling sensation is assessed post application of topically applied menthol, calculated using a 1-10 Rating Scale question on intensity of cooling sensation: scale 1-10, where 1 is a mild cooling sensation, 10 is an extremely intense cooling sensation. |
Retrospective recall data from the end of race questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
|
Rating of Liking from the use of topically applied menthol when used after the marathon
Ramy czasowe: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
|
Average rating for overall liking from the use of topically applied menthol when used after the marathon. Overall liking of cooling sensation is assessed post application of topically applied menthol, calculated using a 1-10 Rating Scale question to rate overall liking of cooling sensation, where 1 is dislike extremely and 10 is like extremely. |
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
|
|
Rating of Liking from the use of topically applied menthol when used during the marathon
Ramy czasowe: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
Average rating for overall liking from the use of topically applied menthol when used during the marathon. Overall liking of cooling sensation is assessed post application of topically applied menthol, calculated using a 1-10 Rating Scale question to rate overall liking of cooling sensation, where 1 is dislike extremely and 10 is like extremely. |
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
|
Percentage agreement that the cooling sensation from topically applied menthol helped to reduce pain.
Ramy czasowe: Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
|
Based on data collected in the Recovery Application Zone Questionnaire, the number of subjects who respond, "strongly agree" and "agree" to Likert Scale statement that the cooling sensation from topically applied menthol helped to reduce pain.
|
Day 1 - immediately at the end of the race, assessed within the Recovery Application Zone Questionnaire.
|
|
Proportion of participants agreement regarding statements about topically applied menthol
Ramy czasowe: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
Participants who respond, "strongly agree" or "agree" to Likert Scale statements in the End of Race Questionnaire:
|
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
|
Percentage of participants experiencing pain relief lasting 2 hours or more after topically applied menthol
Ramy czasowe: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
Based on retrospective recall data from the End of Race Questionnaire, participants who responded to a single-select question: 2 hours to less than 3 hours, 3 hours to less than 4 hours, 4 hours or more |
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
|
Analysis of Covariance (ANCOVA) model to assess association between age and pain outcomes (severity, location), and topically applied menthol use during the marathon
Ramy czasowe: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
To assess impact of the following aspects on pain experience (pain severity and location and topically applied menthol use) during the marathon (based on retrospective recall data from the End of Race Questionnaire): Age (self reported: ranges in years: 18-25; 26-35; 36-45; 46-55; 56-65; 66-75; 76 or older) Pain Severity: (self-rated pain before use & immediately after Biofreeze use, both via Numeric Rating Scales 0-10 where 0 is no pain and 10 is the worst pain imaginable) Pain Location (self-reported pain regions, e.g. pelvis; groin; knee; none of these) Biofreeze Use:
|
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
|
Analysis of Covariance (ANCOVA) model to assess association between sex and pain outcomes (severity, location), and topically applied menthol use during the marathon
Ramy czasowe: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
To assess impact of the following aspects on pain experience (pain severity and location and topically applied menthol use) during the marathon (based on retrospective recall data from the End of Race Questionnaire): Sex (self reported: male; female; non-binary; prefer not to say) Pain Severity: (self-rated pain before use & immediately after Biofreeze use, both via Numeric Rating Scales 0-10 where 0 is no pain and 10 is the worst pain imaginable) Pain Location (self-reported pain regions, e.g. pelvis; groin; knee; none of these) Biofreeze Use:
|
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
|
Analysis of Covariance (ANCOVA) model to assess association between menstrual cycle stage, menopausal status and pain outcomes (severity, location), and topically applied menthol use during the marathon
Ramy czasowe: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
To assess impact of the following aspects on pain experience (pain severity and location and topically applied menthol use) during the marathon (based on retrospective recall data from the End of Race Questionnaire): Menstrual cycle stage and menopausal status (self-reported status; for example Have menstrual cycle, was on my period; Post menopausal) Pain Severity: (self-rated pain before use & immediately after Biofreeze use, both via Numeric Rating Scales 0-10 where 0 is no pain and 10 is the worst pain imaginable) Pain Location (self-reported pain regions, e.g. pelvis; groin; knee; none of these) Biofreeze Use:
|
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
|
Analysis of Covariance (ANCOVA) model to assess association between amount of sleep, quality of sleep the night before the marathon and pain outcomes (severity, location), and topically applied menthol use during the marathon
Ramy czasowe: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
To assess impact of the following aspects on pain experience (pain severity and location and topically applied menthol use) during the marathon (based on retrospective recall data from the End of Race Questionnaire): Amount and quality of sleep the night before the marathon: (self reported: hours slept example: less than 1 hour, 2 hours to less than 3, 3 hours to less than 4, more than 8 hours; Sleep quality: very good; fairly good; fairly bad; very bad) Pain Severity: (self-rated pain before use & immediately after Biofreeze use, both via Numeric Rating Scales 0-10 where 0 is no pain and 10 is the worst pain imaginable) Pain Location (self-reported pain regions, e.g. pelvis; groin; knee; none of these) Biofreeze Use:
|
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
|
Types of oral analgesic products used alongside topically applied menthol
Ramy czasowe: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
Participants reported types of oral analgesia used alongside topically applied menthol during the marathon and recovery period through the following question (option to select): Ibuprofen /Acetaminophen /Opioid /Naproxen /Aspirin / Combination Analgesic / Other.
|
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
|
Number of participants who used analgesic products alongside topically applied menthol for pain relief during marathon
Ramy czasowe: Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
Types of oral analgesia used alongside topically applied menthol and number of participants who used each during the race and recovery period. Participants reported use of oral analgesic products alongside topically applied menthol by single-select (YES/NO) question. |
Retrospective recall data from the End of Race Questionnaire was completed on Day 1: Completed at least 2 hours after the end of the race, up to 23:59 on race day.
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Neeta Yousaf, PHD, Curion Strategic Product Insights
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Ból
- Objawy neurologiczne
- Choroby układu mięśniowo-szkieletowego
- Choroby Układu Nerwowego
- Choroby mięśni
- Choroby nerwowo-mięśniowe
- Ból mięśniowo-szkieletowy
- Stany patologiczne, oznaki i objawy
- Objawy i symptomy
- Ból mięśni
- Administracja usług zdrowotnych
- Jakość opieki zdrowotnej
- Ocena wyników, opieka zdrowotna
- Ocena wyników i procesu, opieka zdrowotna
- Czujne czekanie
Inne numery identyfikacyjne badania
- 5106901
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Ból mięśni
-
Hasan Kalyoncu UniversityJeszcze nie rekrutacjaPrzewlekły ból szyi | Ultrasonograficzne | MASSETER MUSCLETurcja (Türkiye)
-
Xijing HospitalNieznanyPlastyka powiek pod brwiami; Chirurgia powiek podwójnych; Orbicularis Oculi MuscleChiny
-
Karolinska InstitutetJeszcze nie rekrutacjaBól mięśniowo-twarzowy | Myogenne zaburzenia stawu skroniowo -żuchwowego | MASSETER MUSCLESzwecja
-
Melis AKYILDIZRekrutacyjnyWady zgryzu | Przerost migdałka gardłowego | MASSETER MUSCLETurcja (Türkiye)
Badania kliniczne na Observational
-
Zhujiang HospitalZakończonyChoroba wątroby związana z alkoholemChiny